

JOHCM Continental European Fund

Fund overview

- The Fund aims to generate long-term capital growth through active management of a portfolio of European (excluding UK) equities
- Senior Fund Manager Paul Wild employs a pragmatic investment process that combines top-down economic and sector views with bottom-up stock picking
- A core investment style with a focus on European large and mid-cap stocks
- SFDR classification: Article 8. Please click [here](#) for further details
- Benchmark: MSCI Europe ex UK Index
- The use of the Index does not limit the investment decisions of the fund manager therefore the shareholdings of the Fund may differ significantly from those of the Index
- Please refer to the Prospectus/KID for further information

Share class: A EUR Class

ISIN: IE0033009238

Fund details

Fund size	EUR 602.09m
Launch date	5 November 2001
Benchmark***	MSCI Europe ex UK NR Index (12pm adjusted)
No. of holdings	37
Domicile	Ireland
Fund structure	UCITS
Tax status	UK reporting status
Denominations	GBP, EUR, USD
Valuation point	12pm Dublin time
SFDR	Article 8


Fund managers



Paul Wild

Senior Fund Manager

Paul has managed the Fund since 2010. He joined JOHCM in 2003 and has 27 years of industry experience.



Justin MacGregor

Senior Analyst

Justin has worked on the Fund since 2021. He joined JOHCM in 2015 and has 18 years of industry experience.

Performance highlights

Return since launch (%)



Return history

	1m	3m	1yr	3yr	5yr	10yr	SL	Annualised*
A EUR Class	-0.30	0.13	12.85	24.87	62.17	124.65	608.24	9.65
Benchmark	0.39	2.65	12.22	19.25	54.29	108.93	416.57	8.03
Quartile**	4	4	2	1	1	2	1	-

Discrete 12 month performance to end of July

	07.24	07.23	07.22	07.21	07.20	07.19	07.18	07.17	07.16	07.15
A EUR Class	12.85	15.22	-3.96	29.91	-0.03	-1.77	5.57	14.52	-9.34	28.66

Past performance is no guarantee of future performance.

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested. For further information on risks please refer to the Fund's KID and/or the Prospectus.

*Annualised since launch. **Refers to the fund's ranking in a peer group of funds made up from all funds classified as Europe ex UK, by either the Investment Association (IA) or Lipper Global. Funds included may be domiciled in the UK, Ireland, or Luxembourg. Lipper ranking is from A GBP Class.

NAV of Share Class A in EUR, net income reinvested, net of fees. The A EUR Class was launched on 7 May 2003. ***Benchmark: MSCI Europe ex UK NR Index (12pm adjusted). During the period 7 May 2003 to 31 December 2012 the Fund was benchmarked against the FTSE Eurofirst 300 TR Index. For the period 1 January 2013 to present the Fund is benchmarked against the MSCI Europe ex UK NR Index (12pm adjusted). Performance of other share classes may vary and is available on request.

Contact details

Dealing & Investing
+353 1 434 5239

Fax
+353 1 553 9436

Email: JOH_Offshore_TAQueries@ntrs.com



Portfolio analysis (%)

Data as at 31 July 2024

Top 10 holdings

	Absolute	Relative
Novo-Nordisk	8.6	3.6
Deutsche Telekom	5.9	4.9
ASML	5.9	1.5
CRH	4.9	4.9
Novartis	4.3	1.7
Heineken	4.3	4.0
AstraZeneca	4.3	4.3
Veolia	3.8	3.6
AXA	3.7	2.9
Schneider Electric	3.6	2.0
Total	49.3	

Sector breakdown

	Absolute	Relative
Industrials	23.1	5.4
Communication Services	8.5	5.3
Real Estate	3.4	2.5
Information Technology	10.6	0.7
Consumer Staples	8.9	0.2
Utilities	3.8	0.0
Health Care	17.2	-0.4
Materials	4.9	-0.9
Energy	0.0	-3.1
Consumer Discretionary	5.4	-5.3
Financials	10.8	-7.8
Cash	3.3	3.3

Country breakdown

	Absolute	Relative
France	24.4	2.1
Germany	16.3	-0.8
Denmark	13.7	6.3
Netherlands	12.8	2.8
Sweden	6.6	0.3
Switzerland	5.9	-13.8
Spain	5.6	0.3
Italy	5.3	-0.1
Ireland	1.2	0.6
Other	4.9	-1.0
Cash	3.3	3.3

Market cap breakdown

	Absolute	Relative
Large (>EUR 5bn)	91.6	-8.1
Mid (EUR <5bn)	3.8	3.5
Small (EUR <2bn)	1.2	1.2
Cash	3.3	3.3

Attribution & contribution (%)

Stock attribution

Top contributors	Relative return
CRH	0.68
Prismian	0.27
DSV	0.23
Saint-Gobain	0.18
Vonovia	0.16
Top detractors	
Heineken	-0.39
Roche	-0.36
Novo-Nordisk	-0.28
Autoliv	-0.26
ASML	-0.23

Sector attribution*

	Relative return
Materials	0.64
Industrials	0.32
Consumer Discretionary	0.15
Real Estate	0.15
Communication Services	0.05
Energy	0.04
Utilities	-0.11
Financials	-0.14
Information Technology	-0.25
Consumer Staples	-0.46
Health Care	-1.10

*Excludes cash

Please note that due to rounding breakdowns may not add to 100.00%. All Attribution figures are as at end of day and are calculated on a gross basis. Other includes: Austria, Belgium, Finland, Norway, Portugal and non-benchmark countries.



Fund manager's commentary

- The second round of France's Parliamentary elections had a market positive outcome, with the far-right RN party ranking third, leading to potential cohabitation
- The US was in focus due to an assassination attempt on Trump, Biden's withdrawal from the presidential race, unchanged Fed rates, and signs of a weakening labour market
- Stock picking was impacted mainly within healthcare and staples, offset by a strong materials contribution, with underperformance in Novo Nordisk and not owning Roche, while CRH rebounded well

July saw a very small market uptick amidst a degree of relief stemming from France, where in the second round of the Parliamentary elections, the far-right RN party came in third behind the left-wing bloc and Macron's Ensemble party. The participation rate was particularly high at 67.5%, and with no party reaching a majority, cohabitation is in the making. At the EU level, Ursula von der Leyen won a second five-year term as President.

The US was very much in focus, not least with the assassination attempt on Trump and President Biden dropping out of the presidential race. The Fed left rates unchanged, whilst earlier in the month, the CPI inflation data in the US rose a lower-than-expected 0.1% MoM, and the labour market showed signs of weakening. The ECB also left rates unchanged, and they retained a data-dependent approach, with headline inflation expected to stay above target into 2025 against the background of the unemployment rate being at the lowest level since the start of the Euro at 6.4%. Eurozone flash estimate of GDP for Q2 rose 0.3% QoQ, 0.6% YoY, which beat consensus with France and Spain surprising to the upside. Headline inflation increased to 2.6%, with service inflation remaining high and propelled by wages. The ECB bank lending survey showed further improvement with stable lending standards but the first increase in loan demand in two years, particularly for mortgages and consumer credit. Bond yields declined with a rally in front-end yields, with the yield curve showing some steepening.

Stock picking weighed over the period, principally within health care and staples, somewhat offset by a strong materials contribution. The health care headwind was driven by the underperformance in Novo Nordisk and not owning Roche, which rallied on its phase one obesity data. CRH performed particularly well during the month, rebounding from a weaker end to the first half, with its valuation discount to US peers remaining at particularly high levels. The earnings season so far has proved to be somewhat mixed, and small misses have been excessively punished, as was the case with Heineken after a low single-digit EBIT miss in the second quarter, suffering from June's wet weather.

Performance over 1 month	%
Fund - A EUR Class	-0.30
Benchmark	0.39

Statistics

	Annualised since launch
Active share* (%)	73.75
Fund volatility (%)	17.16
Benchmark volatility (%)	17.00
Alpha	1.65
R squared	0.96
Correlation	0.98
Tracking error (%)	3.59
Information ratio	0.45
Sharpe ratio	0.49

Data calculated weekly.

During the period 7 May 2003 to 31 December 2012 the Fund was benchmarked against the FTSE Eurofirst 300 TR Index. For the period 1 January 2013 to present the Fund is benchmarked against the MSCI Europe ex UK NR Index (12pm adjusted).

Fund awards & ratings



Ratings and awards are as at 31 March 2024. © 2024 Morningstar, Inc. All rights reserved. Rating representative of the A EUR Class, as at 30/06/2024. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. This rating is 100% Analyst Driven and based on Data Coverage of 100%. For more detailed information about Morningstar's Medalist Rating, including its methodology, please see <https://shareholders.morningstar.com/investor-relations/governance/Compliance--Disclosure/default.aspx?Source: FWW>

Country registration

	A GBP	A GBP H	B GBP	A EUR	B EUR	A USD H	B USD H
Austria	✓	✗	✓	✓	✓	✓	✓
France	✓	✗	✓	✓	✓	✓	✓
Germany	✓	✗	✓	✓	✓	✓	✓
Ireland	✓	✓	✓	✓	✓	✓	✓
Jersey	✓	✓	✓	✓	✓	✓	✓
Luxembourg	✓	✗	✓	✓	✓	✓	✓
Malta	✗	✗	✓	✗	✓	✗	✓
Netherlands	✓	✗	✓	✓	✓	✓	✓
Singapore	✓	✓	✓	✓	✓	✓	✓
Spain	✓	✓	✓	✓	✓	✓	✓
Sweden	✓	✗	✓	✓	✓	✓	✓
Switzerland	✓	✓	✓	✓	✓	✓	✓
UK	✓	✓	✓	✓	✓	✓	✓

Swiss representative and paying agent

Copies of the fund's current prospectus, key investor information document (KID) and financial statements can be obtained free of charge from the Swiss Representative, 1741 Fund Solutions Ltd., Burggraben 16, 9000 St. Gallen, Switzerland.

Share class details (Further details on additional share classes are available on request)

	ISIN	SEDOL	Bloomberg	WKN	Initial charge	Annual charge	Ongoing charge	Minimum investment*
A EUR Class	IE0033009238	3300923	JHCMUEI ID	A0BLYN	Up to 5%	0.75%	0.83%	£1,000
B EUR Class	IE0033009014	3300901	JHCMUEE ID	A0BLYL	Up to 5%	1.25%	1.33%	£1,000

Performance fee: A performance fee of 15% is payable on the excess if the NAV outperforms the Index Adjusted NAV (as defined in the Fund supplement) on an annual basis. The calculation is performed daily. Any underperformance is carried forward.

Ongoing Charge is as at 31 July 2024.

*Other currency equivalents apply.

Important information

Professional investors only.

Issued and approved in the UK by J O Hambro Capital Management Limited ("JOHCM") which is authorised and regulated by the Financial Conduct Authority. Registered office: Level 3, 1 St James's Market, London SW1Y 4AH. Issued in the European Union by Perpetual Investment Services Europe Limited ("PISEL") which is authorised by the Central Bank of Ireland. Registered office: 24 Fitzwilliam Place, Dublin 2, Ireland D02 T296. References to "JOHCM" below are to either JOHCM or PISEL as the context requires. Perpetual Group is a trading name of JOHCM and PISEL.

This is a marketing communication. Please refer to the fund prospectus and to the KIID / KID before making any final investment decisions.

These documents are available in English at www.johcm.com, and available from PISEL, or (for UK investors) JOHCM, at the addresses set out above.

Information on the rights of investors can be found [here](#)

The distribution of this document in jurisdictions other than those referred to above may be restricted by law ("Restricted Jurisdictions"). Therefore this document is not intended for distribution in any Restricted Jurisdiction and should not be passed on or copied to any person in such a jurisdiction.

The registrations of the funds described in this document may be terminated by JOHCM at its discretion from time to time.

Notice to investors in Switzerland: The representative of the Company in Switzerland is 1741 Fund Solutions Ltd., Burggraben 16, 9000 St. Gallen, Switzerland (the "Representative"). The paying agent of the Company in Switzerland is Telco Bank Ltd, Bahnhofstrasse 4, 6430 Schwyz, Switzerland. The Prospectus, the KIDs, the Instrument of Incorporation / the Constitution, and the annual and semi-annual reports may be obtained free of charge from the Representative. The Company is defined as J O Hambro Capital Management UK Umbrella Fund (domiciled in the UK), Perpetual Investment Services Europe ICAV (domiciled in Ireland) or Regnan Umbrella Fund ICAV (domiciled in Ireland), as relevant.

The investment promoted concerns the acquisition of shares in a fund and not the underlying assets.

Past performance is no guarantee of future performance. The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.

Investing in companies in emerging markets involves higher risk than investing in established economies or securities markets. Emerging Markets may have less stable legal and political systems, which could affect the safe keeping or value of assets.

Investments include shares in small cap companies and these tend to be traded less frequently and in lower volumes than larger companies making them potentially less liquid and more volatile.

The information contained herein including any expression of opinion is for information purposes only and is given on the understanding that it is not a recommendation.

The information in this document does not constitute, or form part of, any offer to sell or issue, or any solicitation of an offer to purchase or subscribe for any funds described in this document; nor shall this document, or any part of it, or the fact of its distribution form the basis of, or be relied on, in connection with any contract.

Telephone calls to and from JOHCM and JOHCM I may be recorded. Information on how personal data is handled can be found in the JOHCM Privacy Statement on its website: www.johcm.com.

The registered mark J O Hambro® is owned by Barnham Broom Holdings Limited and is used under licence. JOHCM® is a registered trademark of JOHCM. Sources: JOHCM/Lipper/MSCI Group (unless otherwise stated)

Certain information contained herein (the "Information") is sourced from/copyright of MSCI Inc., MSCI ESG Research LLC, or their affiliates ("MSCI"), or information providers (together the "MSCI Parties") and may have been used to calculate scores, signals, or other indicators. The Information is for internal use only and may not be reproduced or disseminated in whole or part without prior written permission. The Information may not be used for, nor does it constitute, an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product, trading strategy, or index, nor should it be taken as an indication or guarantee of any future performance. Some funds may be based on or linked to MSCI indexes, and MSCI may be compensated based on the fund's assets under management or other measures. MSCI has established an information barrier between index research and certain Information. None of the Information in and of itself can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user assumes the entire risk of any use it may make or permit to be made of the Information. No MSCI Party warrants or guarantees the originality, accuracy and/or completeness of the Information and each expressly disclaims all express or implied warranties. No MSCI Party shall have any liability for any errors or omissions in connection with any Information herein, or any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.